St Jude Medical announces name change for neuromodulation division17 December 2008 St Jude Medical, Inc. (NYSE:STJ) has announced that its neuromodulation division, formerly Advanced Neuromodulation Systems, has adopted the St Jude Medical name. St Jude Medical, which acquired Advanced Neuromodulation Systems in
2005, develops, manufactures and markets implantable neuromodulation
products with the goal of improving the quality of life for millions of
people who suffer from disabling chronic pain and nervous system
disorders. “St. Jude Medical has consistently demonstrated its commitment to the future of neuromodulation, and the benefits and relief it can offer patients suffering from chronic pain and other neurological disorders,” said Daniel J. Starks, chairman, president and chief executive officer of St. Jude Medical. ”Chronic pain is a growing problem worldwide, with one in five people suffering from this condition.” While there is a large body of literature on the success of SCS, evidence continues to support its safety and effectiveness as a treatment for severe chronic pain. Published reports in Neurosurgery, Spine, The Journal of the American Medical Association and other publications indicate that SCS is more clinically effective than repeated back surgery and more cost effective. In a comprehensive review of more than 30 published studies, findings confirm the effectiveness of SCS as an early treatment option for failed back surgery syndrome patients. In the United Kingdom earlier this year, the National Institute for
Health and Clinical Excellence (NICE) recommended that spinal cord
stimulation be made available to all patients who continue to experience
chronic neuropathic pain for at least six months despite trying
conventional approaches to pain management. To review the NICE guidance,
please visit
www.nice.org.uk/Guidance/TA159. Bookmark this page |
|||